601 related articles for article (PubMed ID: 30956230)
1. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.
Makovec T
Radiol Oncol; 2019 Mar; 53(2):148-158. PubMed ID: 30956230
[TBL] [Abstract][Full Text] [Related]
2. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.
Brabec V
Prog Nucleic Acid Res Mol Biol; 2002; 71():1-68. PubMed ID: 12102553
[TBL] [Abstract][Full Text] [Related]
3. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
4. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.
Hall MD; Okabe M; Shen DW; Liang XJ; Gottesman MM
Annu Rev Pharmacol Toxicol; 2008; 48():495-535. PubMed ID: 17937596
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium(II) and Platinum(II) Complexes with Biologically Active Aminoflavone Ligands Exhibit In Vitro Anticancer Activity.
Fabijańska M; Kasprzak MM; Ochocki J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299199
[TBL] [Abstract][Full Text] [Related]
6. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
7. Molecular aspects of resistance to antitumor platinum drugs.
Brabec V; Kasparkova J
Drug Resist Updat; 2002; 5(3-4):147-61. PubMed ID: 12237082
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
9. Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes.
Palanichamy K; Sreejayan N; Ontko AC
J Inorg Biochem; 2012 Jan; 106(1):32-42. PubMed ID: 22112837
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of resistance and toxicity associated with platinating agents.
Rabik CA; Dolan ME
Cancer Treat Rev; 2007 Feb; 33(1):9-23. PubMed ID: 17084534
[TBL] [Abstract][Full Text] [Related]
11. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
[TBL] [Abstract][Full Text] [Related]
12. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
13. Loss of amine from platinum(II) complexes: implications for cisplatin inactivation, storage, and resistance.
Lau JK; Deubel DV
Chemistry; 2005 Apr; 11(9):2849-55. PubMed ID: 15744707
[TBL] [Abstract][Full Text] [Related]
14. Internalization of Ineffective Platinum Complex in Nanocapsules Renders It Cytotoxic.
Vrana O; Novohradsky V; Medrikova Z; Burdikova J; Stuchlikova O; Kasparkova J; Brabec V
Chemistry; 2016 Feb; 22(8):2728-35. PubMed ID: 26789279
[TBL] [Abstract][Full Text] [Related]
15. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes.
Carter R; Westhorpe A; Romero MJ; Habtemariam A; Gallevo CR; Bark Y; Menezes N; Sadler PJ; Sharma RA
Sci Rep; 2016 Feb; 6():20596. PubMed ID: 26867983
[TBL] [Abstract][Full Text] [Related]
17. Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands.
Marqués-Gallego P; Kalayda GV; Jaehde U; Dulk Hd; Brouwer J; Reedijk J
J Inorg Biochem; 2009 May; 103(5):791-6. PubMed ID: 19303143
[TBL] [Abstract][Full Text] [Related]
18. Platinum-based drugs: past, present and future.
Dilruba S; Kalayda GV
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1103-24. PubMed ID: 26886018
[TBL] [Abstract][Full Text] [Related]
19. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
20. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
